AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Effects: NSAIDs can irritate the lining of the stomach and increase the risk of developing ulcers and gastrointestinal bleeding. This risk is higher in individuals with a history of stomach ulcers, gastrointestinal bleeding, or those who take NSAIDs at high doses or for long periods.
Cardiovascular Effects: Some NSAIDs, particularly certain selective COX-2 inhibitors, have been associated with an increased risk of cardiovascular events such as heart attack and stroke. The risk may vary depending on factors such as the specific NSAID used, dosage, duration of use, and individual cardiovascular risk factors.
Renal (Kidney) Effects: NSAIDs can impair kidney function and may lead to kidney damage, particularly in individuals with pre-existing kidney disease or those who are dehydrated. Long-term use of NSAIDs can also increase the risk of developing chronic kidney disease.
Hepatic (Liver) Effects: Rarely, NSAIDs can cause liver damage or liver failure, especially when taken at high doses or in combination with other medications that affect the liver. It's important to monitor liver function regularly, especially in individuals with pre-existing liver conditions.
Fluid Retention and Hypertension: NSAIDs may cause fluid retention and lead to elevated blood pressure, particularly in individuals with hypertension or heart failure.
Gastrointestinal Symptoms: Common gastrointestinal side effects of NSAIDs include dyspepsia (indigestion), nausea, vomiting, abdominal pain, and diarrhea.
Allergic Reactions: Some individuals may experience allergic reactions to NSAIDs, ranging from mild skin rashes to severe anaphylaxis. People with known allergies to NSAIDs or asthma are at higher risk.
Gastrointestinal Perforation: In rare cases, NSAIDs can cause perforation or a hole in the stomach or intestines, leading to a medical emergency.
Increased Bleeding Risk: NSAIDs can impair platelet function and prolong bleeding time, which may increase the risk of bleeding, particularly in individuals with bleeding disorders or those taking blood-thinning medications.
Interaction with Other Medications: NSAIDs may interact with other medications, including blood thinners, certain antidepressants, and some blood pressure medications, potentially increasing the risk of adverse effects.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | -0.4 | |
Acne | 0.4 | 0.4 | |
ADHD | 0.3 | 0.6 | -1 |
Allergic Rhinitis (Hay Fever) | 0.2 | -0.2 | |
Allergies | 0.8 | 0.8 | 0 |
Allergy to milk products | 1.5 | 1.5 | |
Alopecia (Hair Loss) | 0.6 | -0.6 | |
Alzheimer's disease | 0.8 | 2.6 | -2.25 |
Ankylosing spondylitis | 0.2 | -0.2 | |
Anorexia Nervosa | 0.3 | -0.3 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.6 | 0.6 | |
Atrial fibrillation | 0.6 | 0.6 | 0 |
Autism | 1.8 | 1.2 | 0.5 |
Barrett esophagus cancer | 0.8 | 0.8 | |
Bipolar Disorder | 1 | 0.2 | 4 |
Brain Trauma | 0.5 | 0.2 | 1.5 |
Breast Cancer | 0.2 | -0.2 | |
Carcinoma | 0.2 | 0.7 | -2.5 |
Celiac Disease | 0.6 | 1 | -0.67 |
Cerebral Palsy | 0.2 | -0.2 | |
Chronic Fatigue Syndrome | 0.2 | 1.3 | -5.5 |
Chronic Kidney Disease | 0.6 | -0.6 | |
Chronic Urticaria (Hives) | 0.3 | -0.3 | |
Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | |
Colorectal Cancer | 0.6 | 1.2 | -1 |
Coronary artery disease | 1 | -1 | |
COVID-19 | 0.2 | 2.1 | -9.5 |
Crohn's Disease | 1.5 | 1.8 | -0.2 |
cystic fibrosis | 0.2 | 0.2 | 0 |
deep vein thrombosis | 0.3 | 0.3 | |
Depression | 0.6 | 3 | -4 |
Eczema | 0.2 | -0.2 | |
Endometriosis | 0.2 | 0.2 | |
Epilepsy | 0.4 | -0.4 | |
Functional constipation / chronic idiopathic constipation | 0.2 | 0.6 | -2 |
Generalized anxiety disorder | 0.4 | -0.4 | |
giant cell arteritis | 0.2 | 0.2 | |
Glioblastoma | 0.2 | 0.2 | |
Gout | 1.1 | -1.1 | |
Graves' disease | 0.9 | -0.9 | |
Halitosis | 0.2 | -0.2 | |
Hashimoto's thyroiditis | 0.2 | 0.2 | 0 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.2 | 0.2 | |
Hidradenitis Suppurativa | 0.4 | -0.4 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | -0.2 | |
hypercholesterolemia (High Cholesterol) | 0.8 | 0.2 | 3 |
hyperglycemia | 0.2 | 0.2 | 0 |
hypersomnia | 0.2 | 0.2 | |
hypertension (High Blood Pressure | 0.8 | 1.6 | -1 |
Hypoxia | 0.2 | -0.2 | |
IgA nephropathy (IgAN) | 0.6 | 0.6 | |
Inflammatory Bowel Disease | 0.2 | 0.6 | -2 |
Intelligence | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 0.4 | 1.8 | -3.5 |
Liver Cirrhosis | 1.5 | 1.4 | 0.07 |
Long COVID | 2.6 | 3 | -0.15 |
Low bone mineral density | 0.2 | 0.2 | |
ME/CFS with IBS | 0.2 | 0.2 | 0 |
ME/CFS without IBS | 0.2 | 0.4 | -1 |
Metabolic Syndrome | 2.5 | 3.1 | -0.24 |
Mood Disorders | 1.6 | 3.4 | -1.13 |
multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
Multiple Sclerosis | 0.5 | 1 | -1 |
Multiple system atrophy (MSA) | 0.2 | 0.2 | 0 |
Neuropathy (all types) | 0.2 | -0.2 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 0.6 | -2 |
Obesity | 1.3 | 2 | -0.54 |
obsessive-compulsive disorder | 0.2 | 0.4 | -1 |
Osteoporosis | 0.6 | 0.6 | |
Parkinson's Disease | 0.2 | 1.6 | -7 |
Polycystic ovary syndrome | 1.3 | -1.3 | |
primary biliary cholangitis | 0.6 | 0.6 | |
Psoriasis | 0.2 | 0.4 | -1 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 3.1 | -0.72 |
Rosacea | 0.2 | 0.3 | -0.5 |
Schizophrenia | 0.8 | 1 | -0.25 |
scoliosis | 0.2 | 0.2 | 0 |
Sleep Apnea | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | -0.4 | |
Stress / posttraumatic stress disorder | 0.2 | 1.7 | -7.5 |
Systemic Lupus Erythematosus | 0.2 | 1.3 | -5.5 |
Tic Disorder | 0.2 | 0.2 | 0 |
Type 1 Diabetes | 0.4 | 0.2 | 1 |
Type 2 Diabetes | 0.7 | 1.7 | -1.43 |
Ulcerative colitis | 1 | 1.5 | -0.5 |
Unhealthy Ageing | 0.8 | -0.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.